JP2023540888A5 - - Google Patents
Info
- Publication number
- JP2023540888A5 JP2023540888A5 JP2023512109A JP2023512109A JP2023540888A5 JP 2023540888 A5 JP2023540888 A5 JP 2023540888A5 JP 2023512109 A JP2023512109 A JP 2023512109A JP 2023512109 A JP2023512109 A JP 2023512109A JP 2023540888 A5 JP2023540888 A5 JP 2023540888A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- mutation
- cells
- amino acid
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067629P | 2020-08-19 | 2020-08-19 | |
| US63/067,629 | 2020-08-19 | ||
| PCT/IB2021/000556 WO2022038411A1 (en) | 2020-08-19 | 2021-08-18 | Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540888A JP2023540888A (ja) | 2023-09-27 |
| JP2023540888A5 true JP2023540888A5 (https=) | 2024-08-23 |
Family
ID=78085961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512109A Pending JP2023540888A (ja) | 2020-08-19 | 2021-08-18 | 非天然の改変Ｆｃ受容体に特異的に結合する、ヒトＩｇＧの非天然の改変Ｆｃ領域 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230303658A1 (https=) |
| EP (1) | EP4200325A1 (https=) |
| JP (1) | JP2023540888A (https=) |
| KR (1) | KR20230052279A (https=) |
| CN (1) | CN116322749A (https=) |
| AU (1) | AU2021328717A1 (https=) |
| BR (1) | BR112023003036A2 (https=) |
| CA (1) | CA3189553A1 (https=) |
| IL (1) | IL300484A (https=) |
| MX (1) | MX2023002013A (https=) |
| WO (1) | WO2022038411A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202204016D0 (en) * | 2022-03-22 | 2022-05-04 | Ucl Business Plc | Affinity chromatography ligands for antibody glycovariant separation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| PL209392B1 (pl) * | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2650730A1 (en) * | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| JP2013528357A (ja) * | 2010-03-29 | 2013-07-11 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| US9233125B2 (en) | 2010-12-14 | 2016-01-12 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
| CA3205636A1 (en) | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| FI2838548T3 (fi) | 2012-04-17 | 2023-10-02 | Univ Washington Through Its Center For Commercialization | HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| KR20180075689A (ko) | 2015-11-23 | 2018-07-04 | 트르스티스 오브 보스톤 유니버시티 | 키메라 항원 수용체에 관한 방법 및 조성물 |
| EP3430036A4 (en) | 2016-03-18 | 2019-08-14 | Unum Therapeutics | MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY |
-
2021
- 2021-08-18 BR BR112023003036A patent/BR112023003036A2/pt unknown
- 2021-08-18 CN CN202180050612.XA patent/CN116322749A/zh active Pending
- 2021-08-18 CA CA3189553A patent/CA3189553A1/en active Pending
- 2021-08-18 WO PCT/IB2021/000556 patent/WO2022038411A1/en not_active Ceased
- 2021-08-18 JP JP2023512109A patent/JP2023540888A/ja active Pending
- 2021-08-18 IL IL300484A patent/IL300484A/en unknown
- 2021-08-18 KR KR1020237005773A patent/KR20230052279A/ko active Pending
- 2021-08-18 US US18/021,581 patent/US20230303658A1/en active Pending
- 2021-08-18 EP EP21789807.1A patent/EP4200325A1/en active Pending
- 2021-08-18 MX MX2023002013A patent/MX2023002013A/es unknown
- 2021-08-18 AU AU2021328717A patent/AU2021328717A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7531925B2 (ja) | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 | |
| Crowley et al. | Mind the gap: how interspecies variability in IgG and its receptors may complicate comparisons of human and non-human primate effector function | |
| JP2024144548A5 (https=) | ||
| JP2022162047A5 (https=) | ||
| ES2692206T3 (es) | Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades | |
| ES2423993T3 (es) | Proteínas HLA-G y usos farmacéuticos de las mismas | |
| AU2016363025A1 (en) | Modified chimeric receptors and related compositions and methods | |
| KR102133887B1 (ko) | 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물 | |
| IL101147A (en) | Redirection of cellular immunity by receptor chimeras | |
| US12152065B2 (en) | T cell receptor for identifying AFP antigen | |
| JP2022522404A5 (https=) | ||
| HUE025294T2 (en) | New chemokine-binding polypeptides that are able to inhibit the process of autoimmunity, inflammation and cancer | |
| WO2019091347A1 (zh) | 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途 | |
| Leiden et al. | The complete primary structure of the T-cell receptor genes from an alloreactive cytotoxic human T-lymphocyte clone | |
| CN111655845A (zh) | 代谢调节剂在肿瘤微环境中的表达以改善肿瘤的治疗 | |
| JPH05507911A (ja) | 多発性硬化症ｔ細胞受容体 | |
| KR20160016725A (ko) | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 | |
| JP7606510B2 (ja) | Ｅｂｖ－由来抗原に特異的なｔｃｒ構築物 | |
| CN119895039A (zh) | 突变多肽、包含所述突变多肽的组合物及其用途 | |
| JP2023540888A5 (https=) | ||
| AU2019406447A1 (en) | CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies | |
| EP3496749B1 (en) | Mhc class ia open conformers | |
| Turner et al. | TCR α-chain usage can determine antigen-selected TCR β-chain repertoire diversity | |
| JP2024520952A (ja) | 免疫原性ペプチドを使用した改善された処置方法 | |
| CN114555815A (zh) | T细胞受体及其使用方法 |